<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 47-yr-old woman presented a <z:hpo ids='HP_0003774'>chronic renal failure</z:hpo> for 5 yr, with a <z:chebi fb="0" ids="16737">creatinine</z:chebi> clearance of 12 mL/min </plain></SENT>
<SENT sid="1" pm="."><plain>In June 2002, she had a right axillary lymph node (of 4 cm diameter) </plain></SENT>
<SENT sid="2" pm="."><plain>A biopsy revealed a follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (histology: follicular small cleaved-cell) </plain></SENT>
<SENT sid="3" pm="."><plain>She had Ann Arbor stage III disease, with a high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden according to the GELF criteria </plain></SENT>
<SENT sid="4" pm="."><plain>She received rituximab as single first-line treatment (375 mg/m2 by intravenous infusion for a total of four dosages: days 1, 8, 15 and 22) </plain></SENT>
<SENT sid="5" pm="."><plain>Rituximab therapy was extremely well tolerated, and we obtained a partial response, 4 wk after completing the treatment </plain></SENT>
<SENT sid="6" pm="."><plain>In January 2003, she received one maintenance course of rituximab </plain></SENT>
<SENT sid="7" pm="."><plain>Six weeks after maintenance therapy, a complete response was achieved </plain></SENT>
</text></document>